Ovid Therapeutics Inc. (OVID)
NASDAQ: OVIDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OVID stock chart
Technical analysisKey statistics
All statistics- Market cap
- $415.21M
- EPS (TTM)
- -$0.15
- Dividend yield
- None
- 52-week range
- 1.26 – 3.11
- Day range
- 2.17 – 2.33
- Volume / Avg
- 2.83M / 1.98M
- Beta
- —
- Shares outstanding
- 188.73M
52-week range
OVID stock today
Ovid Therapeutics (OVID) closed at $2.20 on Nov 20, down 5.98% (-$0.14), versus the S&P 500's 3.70% decline. At this level, OVID sits in the middle of its 52-week range of $1.26 to $3.11: 29.1% below the high, set on Apr 9, 2026 and 74.6% above the low. OVID is up 35.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 57.1%.
Ovid Therapeutics has posted a net loss over the last twelve months (EPS of -$0.15), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ovid Therapeutics
Company profileOvid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Margaret Alexander
- Headquarters
- New York, NY
- Employees
- 23
- IPO year
- 2017
- Website
- ovidrx.com
Financial highlights
Full financialsIn fiscal 2025, Ovid Therapeutics generated $7.3 million in revenue, up 1181.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Ovid Therapeutics reported a net loss of $17.4 million, compared with a loss of $26.4 million a year earlier. Operating margin was -585.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.25M | $566.00K | $392.00K | $1.50M | $208.38M |
| Growth | +1181.27% | +44.39% | -73.91% | -99.28% | +1551.57% |
| Net income | $-17.41M | $-26.43M | $-52.34M | $-54.17M | $122.83M |
| EPS (diluted) | — | — | $-0.74 | $-0.77 | $1.76 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$6.15+179.55%
- Strong buy 0
- Buy 13
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.10 vs $-0.08
- Surprise
- -25.00%
OVID news
All OVID news- Ovid Therapeutics Reports Q3 Results; Multiple Pipeline Readouts Expected In 2027NasdaqOVID, BIO.B
- Ovid Therapeutics GAAP EPS of -$0.10 misses by $0.02Seeking Alpha
- Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial ResultsGlobeNewswire
- Cantor Fitzgerald Initiates Coverage of Ovid Therapeutics with Overweight RatingNasdaq
Ovid Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs OVID |
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs OVID |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs OVID |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs OVID |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs OVID |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs OVID |
| OCSOculis Holding AG | 7.06 | -5.11% | $393.35M | vs OVID |
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs OVID |
Indexes, lists and sector
Ovid Therapeutics stock FAQ
What is Ovid Therapeutics's stock price today?
OVID last traded at $2.20 as of Nov 20, 4:00 PM EST, down 5.98% on the day. Prices are delayed at least 15 minutes.
Who is Ovid Therapeutics's CEO?
Ms. Margaret Alexander is the chief executive officer of Ovid Therapeutics Inc., which has about 23 employees.
What is the OVID 52-week high?
The 52-week high for OVID is $3.11 and the 52-week low is $1.26. The stock is currently 29.1% below its high.